Free Newsletter
Sanofi to shutter 370-worker plant in KC
Sanofi-Aventis is exchanging the "For Sale" sign on its Kansas City plant for another that says, "Closed." After scouting for a buyer for more than a year, the drugmaker is shutting down the facility, which employs 370 people. Workers were told during a site meeting late last week.
Apparently, the drugs made in Kansas City weren't growing fast enough for Sanofi. "There were a number of criteria involved in deciding to close, but ultimately, it was a lack of growth in demand for the products," Jack Cox, a Sanofi spokesman, told the Kansas City Star. A few potential buyers kicked around the plant, but ultimately the proposals Sanofi got "weren't sufficient to sustain the facility," Cox said.
The phased shutdown will wrap up by mid-2012, and employees will get a transition bonus and assistance in finding new work. "Our priority will be to help employees ... while gradually reducing our manufacturing levels," site leader Osric Kirk Reavis said in a statement. More details to come by the end of November.
- read the Sanofi release
- see the KC Star article
Related Articles:
1,300 eligible for Sanofi's 'voluntary departures'
Amid Lantus furor, Sanofi restructures
Sanofi to amp up generics push, cut R&D
Sanofi CEO: Think small in Big Pharma
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: